Title:Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment
Volume: 28
Issue: 2
Author(s): Amanda Letícia Polli Silvestre, Joáo Augusto Oshiro-Júnior*, Camila Garcia, Bruna Ortolani Turco, Joandra Maísa da Silva Leite, Bolivar Ponciano Goulart de Lima Damasceno, Jonas Corsino Maduro Soares and Marlus Chorilli*
Affiliation:
- Graduation Program in Pharmaceutical Sciences, State University of Paraiba, Campina Grande, Joao Pessoa,Brazil
- School of Pharmaceutical Sciences, UNESP-Sao Paulo State University, Rodovia Araraquara-Jau, km. 1, Araraquara, Sao Paulo 14800-903,Brazil
Keywords:
Drug delivery nanosystems, biopharmaceuticals, cancer treatment, biosimilars, antibodies, new therapy.
Abstract: Monoclonal antibodies carried in nanosystems have been extensively studied and reported
as a promising tool for the treatment of various types of cancers. Monoclonal antibodies have great
advantages for the treatment of cancer because their protein structure can bind to the target tissue;
however, it has some challenges such as denaturation following heat exposure and extreme values of
pH, temperature and solvents, the ability to undergo hydrolysis, oxidation and deamination and the
formation of non-native aggregates, which compromise drug stability to a large extent. In addition to
these characteristics, they suffer rapid elimination when in the blood, which results in a short half-life
and the production of neutralizing antibodies, rendering the doses ineffective. These challenges are
overcome with encapsulation in nanosystems (liposomes, polymer nanoparticles, cyclodextrins, solid
lipid nanoparticles, nanostructured lipid carriers, dendrimers and micelles) due to the characteristics
of improving solubility, permeability, and selectivity only with tumor tissue; with that, there is a decrease
in side effects beyond controlled release, which is critical to improving the therapeutic efficacy
of cancer treatment. The article was divided into different types of nanosystems, with a description of
their definitions and applications in various types of cancers. Therefore, this review summarizes the
use of monoclonal antibodies encapsulated in nanosystems and the description of clinical studies with
biosimilars. Biosimilars are defined as products that are similar to monoclonal antibodies which are
produced when the patent for the monoclonal antibodies expires.
